Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Not all profitable companies are created equal, and that’s why we built StockStory - to help you find the ones that truly shine bright. Keeping that in mind, here are two profitable companies that generate reliable profits without sacrificing growth and one best left off your watchlist.
One Stock to Sell:
B&G Foods (BGS)
Trailing 12-Month GAAP Operating Margin: 2.8%
Started as a small grocery store in New York City, B&G Foods (NYSE: BGS) is an American packaged foods company with a diverse portfolio of more than 50 brands.
Why Should You Dump BGS?
- Products have few die-hard fans as sales have declined by 5.4% annually over the last three years
- Earnings per share decreased by more than its revenue over the last three years, partly because it diluted shareholders
- High net-debt-to-EBITDA ratio of 7× increases the risk of forced asset sales or dilutive financing if operational performance weakens
B&G Foods’s stock price of $4.41 implies a valuation ratio of 8.3x forward P/E. To fully understand why you should be careful with BGS, check out our full research report (it’s free).
Two Stocks to Watch:
MYR Group (MYRG)
Trailing 12-Month GAAP Operating Margin: 5.2%
Constructing electrical and phone lines in the American Midwest dating back to the 1890s, MYR Group (NASDAQ: MYRG) is a specialty contractor in the electrical construction industry.
Why Do We Watch MYRG?
- Performance over the past two years was turbocharged by share buybacks, which enabled its earnings per share to grow faster than its revenue
- Free cash flow margin grew by 4.5 percentage points over the last five years, giving the company more chips to play with
- Stellar returns on capital showcase management’s ability to surface highly profitable business ventures
MYR Group is trading at $473.39 per share, or 39x forward P/E. Is now the time to initiate a position? Find out in our full research report, it’s free.
ANI Pharmaceuticals (ANIP)
Trailing 12-Month GAAP Operating Margin: 13.4%
With a diverse portfolio of 116 pharmaceutical products and a growing rare disease platform, ANI Pharmaceuticals (NASDAQ: ANIP) develops, manufactures, and markets branded and generic prescription pharmaceuticals, with a focus on rare disease treatments.
Why Are We Fans of ANIP?
- Annual revenue growth of 33.6% over the past two years was outstanding, reflecting market share gains this cycle
- Free cash flow margin jumped by 38.4 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends
- Improving returns on capital suggest its past investments are beginning to deliver value
At $80.42 per share, ANI Pharmaceuticals trades at 1.5x forward price-to-sales. Is now the right time to buy? See for yourself in our full research report, it’s free.
Stocks We Like Even More
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
